• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics Cardiology Classics

The DAPA-HF trial: Dapagliflozin in patients with heart failure [Classics Series]

byDeepti Shroff, DMD, MS
June 10, 2022
in Cardiology Classics, The Classics
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. This study found that patients with heart failure with reduced ejection fraction (HFrEF) who received dapagliflozin had lower rates of composite cardiovascular death and worsening heart failure (16.3%) compared to controls (21.1%).

2. Presence or absence of diabetes had no significant impact on the outcomes in either group.

Original Date of Publication: November 2019

Study Rundown: The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial evaluated the cardioprotective effects of the sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in patents with HFrEF. Composite cardiovascular death and worsening heart failure was significantly lower in those taking dapagliflozin as compared to placebo. Although SGLT2 inhibitors are typically used in diabetic patients, the presence or absence of diabetes did not alter outcomes in either group. The secondary composite outcome of cardiovascular death and hospitalizations for heart failure was also significantly reduced in the dapagliflozin group. The main limitation of the DAPA-HF trail was limited diversity in the study population, possibly impacting generalizability of the results. The DAPA-HF trial was the first study to demonstrate that in HFrEF patients both with and without diabetes, dapagliflozin reduces progression of heart failure, associated hospitalizations, and risk of cardiovascular death.

Click to read the study in the NEJM (New England Journal of Medicine)

EvidencePulse™by 2 Minute Medicine®

How does DAPA-HF apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

In-Depth [randomized control trial]: The DAPA-HF trial was conducted on a group of HFrEF patients (n = 4744) who were randomized into either a dapagliflozin group (n = 2373) or placebo (n = 2371) for a median duration of follow-up of 18.2 months. All trial outcomes were adjudicated by a blinded clinical-events committee. The primary composite endpoint of cardiovascular death and worsening heart failure characterized by hospitalization or urgent primary care visit resulting in intravenous therapy was significantly lower in the dapagliflozin group (16.3%) than the placebo group (21.2%) (HR 0.74; 95%CI 0.65-0.85). The dapagliflozin group also had a significantly reduced rate of the composite outcome of cardiovascular death and hospitalization due to heart failure (HR 0.75; 95%CI 0.65-0.85). Both groups were matched at screening for type 2 diabetes (42%) and diabetes status did not have any impact on the primary or the secondary composite outcomes.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019 Nov 21;381(21):1995–2008.

Trials since this one

What later trials found on the same question.

  1. 2020

    EAST-AFNET 4 In The Classics

    The EAST-AFNET 4 trial (East AF) demonstrated that early rhythm control therapy—including antiarrhythmic drugs or catheter ablation—was associated with a significant reduction in the composite outcome of cardiovascular…

  2. 2020

    VICTORIA In The Classics

    This study found that patients with chronic heart failure and reduced ejection fraction who received vericiguat had lower rates of composite cardiovascular death and first hospitalization for heart failure (35.5%)…

1 more since 2019

2MM+ See every trial since DAPA-HF

2MM+ shows the full timeline of later trials on this question, with what each one found, and lets you save trials to reading lists for rounds, journal club and boards.

See 2MM+ plans Sign in

Citation: McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/nejmoa1911303. Epub 2019 Sep 19. PMID: 31535829.

© 2022 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

Tags: dapagliflozinHFrEF (heart failure with reduced ejection fraction)SGLT-2 inhibitors

Our coverage

  • Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER Oct 2022

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Cardiology Classics

Previous Post

Interventions prompted by primary care providers increases physical activity

Next Post

#VisualAbstract: Whole-genome sequencing changes clinical management in significant number of critically ill infants

Next Post
#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

#VisualAbstract: Whole-genome sequencing changes clinical management in significant number of critically ill infants

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cretostimogene reduced recurrence risk in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer in topline phase 3 results
  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.